Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of PD1-TIM3 bispecific antibody RO7121661 and PD1-LAG3 bispecific antibody RO7247669 versus nivolumab in advanced or metastatic esophageal squamous cell carcinoma
2020-004606-60Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing RO7121661 arm, RO7247669 arm and Nivolumab arm (3 arms). Primary endpoint: Overall survival. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2020-004606-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004606-60.